- Home
- ATCX vs NRSN Comparison
ATCX vs NRSN Comparison
Compare ATCX & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATCX | NRSN |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | Brazil | Israel |
| Employees | 13 | 15 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.5M | 29.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ATCX | NRSN |
|---|---|---|
| Price | $7.10 | $0.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 70.9K | ★ 148.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.32 | $0.68 |
| 52 Week High | $14.01 | $2.60 |
Technical Indicators
Market Signals| Indicator | ATCX | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 50.03 | 43.03 |
| Support Level | $5.93 | $0.68 |
| Resistance Level | $14.01 | $1.30 |
| Average True Range (ATR) | 0.79 | 0.07 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 70.42 | 15.63 |
Price Performance
Historical ComparisonAbout ATCX Atlas Critical Minerals Corporation Common Stock
Atlas Critical Minerals Corporation, is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.